European Patent Office Grants PAR Key Respiratory Patent
Released
Released
Announcement PDF
ASX RELEASE
Paradigm Biopharmaceuticals secures key European patent
Highlights:
European Patent Office grants Paradigm key respiratory patent.
Patent to use Pentosan Polysulfate Sodium (PPS) to treat respiratory diseases.
Patent claims the use of PPS over allergic rhinitis, allergic asthma and COPD.
Allergic rhinitis (AR) or as it is more commonly referred to “hay fever” is a very common
disease, affecting 10% to 30% of the world’s population.
15 December 2015, Melbourne Australia: Paradigm Biopharmaceuticals Limited (ASX:PAR) is
pleased to advise it has been issued with a 71(3) communication, notice of intention to grant a patent
by the European Patent Office (EPO).
Paradigm’s patent attorney Paul Whenman from the firm FB Rice & Co said “the EPO 71(3)
communication, notice of intention to grant a patent means that prosecution of the patent application
has been finalized and the EPO will grant a patent once Paradigm has provided the requisite
translations and paid the official grant fees. Upon grant of the patent, Paradigm will have market
exclusivity under the patent until 30 May 2028. Since the patent claims the use of PPS for the
treatment of allergic rhinitis, allergic asthma and COPD, Paradigm will have exclusivity for these
indications while the patent is in force.
The granting of this respiratory patent in Europe adds to Paradigm’s growing intellectual property
portfolio. Paradigm’s bone marrow edema (BME) patent is already granted in the USA, Australia and
New Zealand. In addition Paradigm’s PPS respiratory patent is already granted in China, Australia and
New Zealand.
Mr Whenman also said “the prosecution of Paradigm’s BME and respiratory patents continues in other
major markets, such as Japan, Canada & China, where it is expected that more Paradigm patents will
be granted in 2016”.
In addition to patents, Paradigm has registered trademarks for the BME product, ZILOSUL® and
respiratory product RHINOSUL® for Allergic Rhinitis.
Enquiries:
Paul Rennie
Managing Director and CEO
0437 778 300
Rudi Michelson
Monsoon Communications
03 9620 3333 or 0411 402 737
About Allergic Rhinitis: Allergic rhinitis (AR) or, as it is more commonly referred to, hay fever, is a very common disease,
affecting 10% to 30% of the world’s population and 7.8% of adults in the US (or, approximately, 25 million Americans)
according to figures quoted by the American Academy of Allergy, Asthma and Immunology. AR is the result of the immune
system over-reacting to allergens, such as pollen, dust and/or pet hair, in the air. Two common therapies for treating AR
include antihistamines and intranasal corticosteroids.
About Paradigm Biopharmaceuticals: Paradigm Biopharmaceuticals (ASX:PAR) is an Australian biopharmaceutical
company focused on repurposing historic drug PPS (Pentosan Polysulphate Sodium) as a potential new treatment for Bone
Marrow Edema (BME) lesions arising from sporting injuries as well as for respiratory diseases including Allergic Rhinitis
(AR), or hay fever.
PPS is a well-established anti-clotting and anti-inflammatory agent that has been used for over 60 years to treat interstitial
cystitis and the prevention and treatment of deep vein thrombosis. It has a solid safety and efficacy profile.
BME is also known as bone bruising and is an extremely painful and debilitating injury. It typically affects sportspeople but
can also result from a range of injuries including car accidents and falls. BME is caused by fluid build-up and micro-fractures
inside the bone, causing severe pain. There is no approved pharmaceutical product to treat this condition. Current
treatment of BME includes the use of steroidal and non-steroidal anti-inflammatory drugs, which can have serious side
effects. Paradigm will launch an Open Label clinical trial of PPS in BME trial subjects at sites in Australia from early 2016.
Paradigm has also acquired patents over the use of PPS as a new treatment for respiratory diseases including Allergic
Rhinitis (AR), Allergic Asthma (AA) and Chronic Obstructive Pulmonary Disease (COPD). Paradigm also acquired preclinical data, nasal formulation and other data from the previous developer Glycan BioSciences LLC, allowing Paradigm to
fast-track its treatment for AR into clinical trials in Q4 2016.
Antihistamines and corticosteroid nasal sprays are standard existing treatments for AR. Long-term use of corticosteroids is
associated with adverse side effects whereas Paradigm’s AR product is not a steroid-based pharmaceutical. Paradigm’s
preclinical data demonstrates PPS is both a mast cell stabilizer (reduces mast cell degranulation and therefore PPS acts like
an anti-histamine) and an anti-inflammatory (like a corticosteroid but PPS is not a steroid-based drug). Therefore and very
importantly, PPS is potentially the first dual-acting (effective in both the early and late AR responses) product that could
enter the very large market of AR.
Repurposing an existing drug diminishes early developmental risks associated with traditional new drug development and
usually means shorter development times, lower development costs and less safety risk.
Paradigm has also acquired intellectual property over exosomes; a new technology in stem-cells and regenerative medicine
fields. This technology offers the company the potential to participate in the development of new generation regenerative
medicine products.
Share your feedback
Discover